Loading…
Loading…
EQUITY / NASDAQ · XNCM
Citius Pharmaceuticals, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.531 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 0.531 USD · Volume 127,198
21 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 3 | 2025 / Quarter 3 | Change |
|---|---|---|---|
| Revenue | 1,493,788 USD | — | — |
| Operating profit | -11,732,074 USD | -8,788,007 USD | — |
| Net income | -11,919,260 USD | -9,203,872 USD | — |
| Cash and cash equivalents | 17,007,523 USD | — | — |
| Total liabilities | 66,346,742 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 304/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 301/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 210/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 309/30/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Year end10/01/2024 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 304/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 17,007,523 USD | — | — | — | — | 4,252,290 USD | 4,252,290 USD | — |
| Gross profitIncome statement | 1,001,945 USD | 5,495,268 USD | — | 4,493,323 USD | — | — | — | — |
| Net incomeIncome statement | -11,919,260 USD | -49,422,895 USD | -28,109,746 USD | -37,503,635 USD | -9,393,889 USD | — | -39,740,269 USD | -9,203,872 USD |
| Operating profitIncome statement | -11,732,074 USD | -52,946,068 USD | — | -41,213,994 USD | — | — | -38,525,608 USD | -8,788,007 USD |
| RevenueIncome statement | 1,493,788 USD | 7,105,197 USD | — | 5,611,409 USD | — | — | — | — |
| Total assetsBalance sheet | 142,255,198 USD | — | — | — | — | 130,938,025 USD | 130,938,025 USD | — |
| Total equityBalance sheet | 66,613,132 USD | — | 69,084,553 USD | — | 93,467,970 USD | 67,550,178 USD | 67,550,178 USD | 67,560,930 USD |
| Total liabilitiesBalance sheet | 66,346,742 USD | — | — | — | — | 53,410,425 USD | 53,410,425 USD | — |
| Financing cash flowCash flow statement | — | 42,741,646 USD | — | 19,646,727 USD | — | — | 33,303,148 USD | — |
| Investing cash flowCash flow statement | — | -7,000,000 USD | — | -5,000,000 USD | — | — | -5,750,000 USD | — |
| Operating cash flowCash flow statement | — | -22,986,413 USD | — | -14,308,843 USD | — | — | -26,552,738 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 12/23/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.